Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01062438|
Recruitment Status : Completed
First Posted : February 4, 2010
Last Update Posted : May 6, 2015
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at DNA in tumor tissue samples from patients with localized or metastatic osteosarcoma.
|Condition or disease||Intervention/treatment|
|Sarcoma||Genetic: DNA analysis Genetic: RNA analysis Genetic: gene expression analysis Genetic: gene rearrangement analysis Genetic: mutation analysis Other: laboratory biomarker analysis|
- Determine the genomic expression profile in tumor tissue samples from patients with localized or metastatic osteosarcoma using transcriptome sequencing.
- Identify activating and loss of function mutations and gene rearrangement in these tumor tissue samples using transcriptome sequencing.
- Identify candidate genes that are important in osteosarcoma and tumorigenesis using genome partition strategies for genomic DNA sequencing.
- Identify which mutations are associated with outcome.
- Establish which mutations are also found in germ line DNA that predispose the patient to osteosarcoma.
OUTLINE: DNA and RNA from banked tumor tissue samples and DNA from paired blood samples are analyzed in sequencing studies using next-generation sequencing technology. The sequencing data from these tumor samples are matched to the Human RefSeq (for transcriptome sequencing) and normal human genome in the public databases and to the patient's germ line sequence to identify constitutional and somatic mutations.
Clinical information that is associated with each sample (i.e., age, tumor site, size, primary metastases, response to chemotherapy, surgical remission, follow-up time, and treatment protocol) is also collected, if available.
|Study Type :||Observational|
|Actual Enrollment :||99 participants|
|Official Title:||Genomic Study of Metastatic Osteosarcoma Using Next-Generation Sequencing Technology|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||September 2011|
- Genomic expression profile in osteosarcoma tumor samples using transcriptome sequencing
- Identification of activating and loss of function mutations and gene rearrangement using transcriptome sequencing
- Mutations associated with outcome
- Mutations also found in germ line DNA that predispose the patient to osteosarcoma
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01062438
|Principal Investigator:||Javed Khan, MD||NCI - Oncogenomics Section|